- Follows U.S. FDA IND approval granted in March
- cMET target and PBX-7016 payload application for 바카라사이트 총판 승리바카라
[by Ji, Yong Jun] Celltrion’s antibody-drug conjugate (ADC) anticancer candidate, ‘CT-P70 (development code),’ is entering clinical trials for the first time in Korea.
On May 2, the Ministry of Food and Drug Safety approved 바카라사이트 총판 승리바카라’s investigational new drug (IND) application for the Phase 1 clinical trial of CT-P70 in Korea, marking the first human administration of the candidate. The trial is designed to assess the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of CT-P70 in adult patients with advanced solid tumors. Additionally, 바카라사이트 총판 승리바카라 secured approval from the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical trial in March and plans to initiate patient administration within the year.
CT-P70 is an ADC anticancer candidate targeting the ‘hepatocyte growth factor receptor (cMET),’ which is activated in cancer cells and plays a role in promoting tumor progression. The ADC incorporates a new payload, ‘PBX-7016,’ a platform technology that offers superior safety over existing payloads. 바카라사이트 총판 승리바카라 highlights that PBX-7016 is anticipated to enhance the tumor penetration effect through high-dose administration with reduced toxicity.
According to 바카라사이트 총판 승리바카라, CT-P70 demonstrated significant tumor-suppressive effects in various solid tumor models, including lung, colon, and gastric cancers, based on findings from prior non-clinical studies such as in vitro and animal models.
Based on its therapeutic efficacy and safety profile, 바카라사이트 총판 승리바카라 anticipates that CT-P70 could be applied to the treatment of solid tumors such as non-small cell lung cancer, colon cancer, and gastroesophageal cancer. The company aims to advance the development of CT-P70 as a ‘best-in-class’ therapeutic, striving to achieve superior competitiveness among drugs with a similar mechanism of action.